Related Experiment Videos
[What does remain about bronchopulmonary dysplasia?]
Insights
Bronchopulmonary dysplasia (BPD) in premature infants, a prolonged respiratory issue from neonatal intensive care, shows a declining trend. Advances in neonatal care and preventive therapies offer hope for reduced long-term functional impairment in affected adults.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Respiratory Physiology
Background:
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants, stemming from initial respiratory issues and pulmonary immaturity.
- Historically, BPD posed a significant mortality risk (up to 20%) for infants requiring prolonged mechanical ventilation in neonatal intensive care units.
- Despite a rising preterm birth rate, substantial progress has been made in managing BPD.
Discussion:
- Current preventive strategies include antenatal corticosteroids, exogenous surfactant administration, and improved ventilatory support techniques.
- Enhanced neonatal care, pain management, and nutritional support play crucial roles in BPD management.
- While inhaled corticosteroids have not proven effective, salbutamol spray aids in reducing bronchospasm and improving respiratory compliance.
Key Insights:
- Significant advancements in neonatal care and preventive therapies are leading to a regression in the incidence and severity of bronchopulmonary dysplasia.
- The long-term functional impairment associated with BPD into adulthood is a critical concern, with current data suggesting a more optimistic outlook for current generations.
- Despite challenges, the overall trend indicates a decrease in BPD, though predicting the future remains complex due to the high number of premature births.
Outlook:
- Further reduction in BPD incidence may be achieved through enhanced collaboration between obstetricians and pediatricians.
- Expanding the use of antenatal corticosteroid therapy and refining continuous positive airway pressure (CPAP) ventilation are key areas for future prevention.
- Continued research and development in neonatal respiratory support and therapeutic interventions are essential for improving outcomes for premature infants at risk of BPD.
Abstract:
Bronchopulmonary dysplasia is defined as prolonged respiratory failure resulting from sequellae after neonatal intensive care in premature infants. Functional impairment continues into adult life. There are two main causal factors: the initial respiratory disease and pulmonary immaturity. Up through the nineties, bronchopulmonary dysplasia was a major problem in neonatal intensive care units; mortality reached 20% of infants requiring artificial ventilation for 1 or 2 months. Despite the rising rate of premature births (currently 2%) considerable progress has been made in the treatment of bronchopulmonary dysplasia. The question is whether the infants in the current generation with still suffer into adult life. Advances in preventive therapy have included antenatal corticosteroid therapy, use of exogenous surfactants and progressive improvement in ventilatory assistance techniques. Improved neonatal care to relieve pain and maintain nutrition have also had an important effect. Specific treatments include the use of salbutamol spray to reduce bronchospasme and improve respiratory compliance. The initial hopes placed in inhaled corticosteroids were unfortunately recently shown to be unfounded. Due to the large number of premature infants it appears difficult to predict the future situation of bronchopulmonary dysplasia, but current data show a clear tendancy towards regression of the disease. Three preventive measures could further reduce the incidence: better coordination between obstetricians and pediatricians, extension of antenatal corticosteroid therapy and the development and improvement of continuous positive pressure ventilation.